Q-omics provides the consensus-scored FAM172A profile across patient tissues and cancer cell-line models. FAM172A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM172A is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, FAM172A protein abundance shows 29,770 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LIHC, and GBM as cancer lineages where FAM172A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM172A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM172A survival associations across molecular data types. FAM172A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM172A RNA expression–survival associations across cancer types. High FAM172A expression shows unfavorable associations in KICH, LGG, KIRP and SCLC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM172A RNA expression.
This table summarizes FAM172A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for FAM172A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM172A shows lower tumor expression in UCEC, BLCA, THCA, KICH and BRCA and higher tumor expression in LIHC. The LIHC box plot shows higher FAM172A RNA expression in tumor versus normal tissue (log2 FC = +0.771, t-test p < 0.001).
This table shows molecular features associated with FAM172A in patient tissues and cancer cell lines. In patient samples, FAM172A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM172A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
